Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 primary prophylaxis guided by the XL-CTIT-PP risk model for oxaliplatin-induced thrombocytopenia
ChiCTR2600131326Phase 2Not yet recruiting
- Sponsor
- Xiamen University Zhongshan Hospital
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romiplostim in chemotherapy-induced thrombocytopenia (CIT), sponsored by Xiamen University Zhongshan Hospital. Primary endpoint: Incidence of any-grade chemotherapy-induced thrombocytopenia. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on ChiCTR2600131326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131326.